Julie R. Park, MD
Cancer and Blood Disorders Center, Neuroblastoma Program, Bone Tumors and Soft Tissue Tumors, I-131-MIBG Therapy
On staff since October 1996
Children's Title: Bushnell, Towne and Wilkerson Endowed Chair in Pediatric Neuroblastoma and Medical Director Immunotherapy Coordinating Center
Academic Title: Professor of Pediatrics, UW School of Medicine; Associate, Clinical Research Division, Fred Hutchinson Cancer Research Center
Research Center: Center for Clinical and Translational Research
-
Julie R. Park, MD, is attending physician at Seattle Childrens Hospital, professor in pediatrics at the University of Washington School of Medicine and associate in the Clinical Research Division at Fred Hutchinson Cancer Research Center (FHCRC). She is director of the pediatric hematology-oncology fellowship at the University of Washington.
Julie R. Park, MD, is attending physician at Seattle Children’s Hospital, professor in pediatrics at the University of Washington School of Medicine and associate in the Clinical Research Division at Fred Hutchinson Cancer Research Center (FHCRC). She is medical director of Immunotherapy Coordinating Center within the Immunotherapy Integration Hub and is medical director of the Cancer and Blood Disorders Advanced Therapeutics clinical research program.
Dr. Park’s primary research focus has been investigating novel therapies for the treatment of refractory and recurrent cancers with a specific focus on high-risk neuroblastoma, a rare but aggressive form of childhood cancer. Park is an active member of the Children’s Oncology Group Consortium and as chair of the COG Neuroblastoma Scientific Committee provides leadership for the development of neuroblastoma clinical research within COG. Within COG, she conducted a multi-center clinical trial to determine the feasibility and toxicity of a novel induction chemotherapy regimen for high risk neuroblastoma which has become the backbone induction regimen used in North America. Within COG, Dr. Park also led a randomized clinical trial that determined the benefit of tandem transplant as consolidation therapy for high risk neuroblastoma and was instrumental in the development of chemo-immunotherapy regimen that has proven benefit for children with recurrent or refractory neuroblastoma. In addition to COG, Dr. Park collaborates with investigators through North America as the Scientific Medical Director for the New Approaches to Neuroblastoma Therapy (NANT), developing novel targeted therapies for children with recurrent and refractory neuroblastoma. Dr. Park also collaborates closely with Drs. Jensen and Gardner in the development and implementation of novel cellular immunotherapy approaches for children with recurrent and refractory cancers.
-
Related Pages
-
Gaining Ground on Neuroblastoma
We helped show that two stem cell transplants, plus immunotherapy, significantly increased survival for children with high-risk neuroblastoma.
-
-
-
Dr. Park is my daughter's Doctor. Just saying those words bring hope. I know Dr. Park is absolutely invested in saving children's lives and that she works tirelessly at finding new ways to do so. We may have traveled off the beaten path, where treatment for my daughter is concerned, but only to find that Dr. Park has laid pavement. Not sure what the outcome for my child will be, but I know that Dr. Park is doing all she can to save her. Thank you Dr. Park.
-
Dr. Park did a wonderful job in her medical treatment of my daughter! We began the journey full of fears and worries, and we are so fortunate to have had the best possible outcome. I firmly believe that much of this is due to Dr. Park's wealth of experience, close monitoring and her willingness to listen to my concerns. I always feel that my daughter's best interests are Dr. Park's primary concern, and she has always been very compassionate and caring towards me - even when I was having a hard time coming to grips with what was happening. Anyone who has Dr. Park as their child's oncologist is very lucky to have her!
-
-
Award Name Award Description Awarded By Award Date SEATTLE'S TOP DOCTOR - 2019 Seattle Magazine 2019 SEATTLE'S TOP DOCTOR - 2018 Seattle Magazine 2018 Frank Oski Award American Society of Pediatric Hematology and Oncology 2018 SEATTLE'S TOP DOCTOR - 2017 Seattle Magazine 2017 Seattles Top Doctor 2016 Seattle Met Magazine 2016 SEATTLE MAGAZINE TOP DOCTOR - 2016 Seattle Magazine 2016 SEATTLE MAGAZINE TOP DOCTOR - 2015 Seattle Magazine 2015 SEATTLE MAGAZINE TOP DOCTOR - 2014 Seattle Magazine 2014 Seattle's Top Doc Seattle Met Magazine 2013 Seattle Magazine Top Doctor - 2013 Seattle Magazine 2013 Seattle Magazine Top Doctor - 2012 Seattle Magazine Top Doctor - 2012 Seattle Magazine 2012 U.S. News Top Doctor U.S. News and World Report 2012 Benjamin Towne Endowed Chair in Neuroblastoma Benjamin Towne Foundation 2009 Newsweek Health: Top Cancer Doctors 2015 Newsweek 2015 -
Other Publications
-
Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FMTime to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children's Oncology Group (ANBL0621).
24347462 Pediatric blood & cancer, 2013 Dec. 18 -
Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada HNeuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
23901000 Cancer, 2013 Oct. 15 : 119(20)3718-26 -
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JGPurged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
23890779 The lancet oncology, 2013 Sept. : 14(10)999-1008 -
Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SAA pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1.
23334272 Bone marrow transplantation, 2013 July : 48(7)947-52 PMCID:PMC3638062 -
Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KM, Hogarty M, COG Neuroblastoma CommitteeChildren's Oncology Group's 2013 blueprint for research: neuroblastoma.
23255319 Pediatric blood & cancer, 2013 June : 60(6)985-93 -
Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P, Matthay KKSemiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.
23440556 Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013 April : 54(4)541-8 -
Suganuma R, Wang LL, Sano H, Naranjo A, London WB, Seeger RC, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Amann G, Beiske K, Cullinane CJ, d'Amore ES, Gambini C, Jarzembowski JA, Joshi VV, Navarro S, Peuchmaur M, Shimada HPeripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
22744966 Pediatric blood & cancer, 2013 March : 60(3)363-70 PMCID:PMC3397468 -
Moreno L, Barone G, Park JR, Pearson ADAbout the benefits of immunotherapy for high-risk neuroblastoma.
23295791 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013 Feb. 10 : 31(5)649-50 -
Gross TG, Orjuela MA, Perkins SL, Park JR, Lynch JC, Cairo MS, Smith LM, Hayashi RJLow-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.
22883417 American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2012 Nov. : 12(11)3069-75 PMCID:PMC3484187 -
Glade Bender J, Blaney SM, Borinstein S, Reid JM, Baruchel S, Ahern C, Ingle AM, Yamashiro DJ, Chen A, Weigel B, Adamson PC, Park JRA phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report.
22791883 Clinical cancer research : an official journal of the American Association for Cancer Research, 2012 Sept. 15 : 18(18)5081-9 PMCID:PMC3445751 -
Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, Frazier J, Chau BN, Loboda A, Linsley PS, Cleary MA, Park JR, Grandori CFunctional genomics identifies therapeutic targets for MYC-driven cancer.
22623531 Proceedings of the National Academy of Sciences of the United States of America, 2012 June 12 : 109(24)9545-50 PMCID:PMC3386069 -
Fisher BT, Zaoutis TE, Park JR, Bleakley M, Englund JA, Kane C, Arceci RJ, Guinan E, Smith FO, Luan X, Marr KAGalactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients.
23687575 Journal of the Pediatric Infectious Diseases Society, 2012 June : 1(2)103-111 PMCID:PMC3656552 -
Raccor BS, Claessens AJ, Dinh JC, Park JR, Hawkins DS, Thomas SS, Makar KW, McCune JS, Totah RAPotential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo.
21976622 Drug metabolism and disposition: the biological fate of chemicals, 2012 Jan. : 40(1)54-63 PMCID:PMC3250049 -
Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, Shaw PJ, Cohn SL, Matthay KKPilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.
22010014 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011 Nov. 20 : 29(33)4351-7 PMCID:PMC3221519 -
Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S, Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM, Maris JMPhase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.
21340605 Cancer chemotherapy and pharmacology, 2011 Oct. : 68(4)1057-65 -
Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JGA phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.
21671363 Pediatric blood & cancer, 2011 Aug. : 57(2)275-82 PMCID:PMC3117015 -
Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, Zwiebel J, Blaney SM, Adamson PCPediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
20606092 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010 Aug. 1 : 3623-9 -
Park JR, Eggert A, Caron HNeuroblastoma: biology, prognosis, and treatment.
20113896 Hematology/oncology clinics of North America, 2010 Feb. : 65-86 -
Fong A, Park JRHigh-risk neuroblastoma: a therapy in evolution.
19954363 Pediatric hematology and oncology, 2009 Nov. : 539-48 -
Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KKPhase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
19171709 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009 March 10 : 1290-6 -
Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, Attiyeh EF, Maris JM, Seeger RC, Reynolds CP, Matthay KKOutcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group.
18937318 Pediatric blood & cancer, 2009 Jan. : 44-50 -
McCune JS, Salinger DH, Vicini P, Oglesby C, Blough DK, Park JRPopulation pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group.
18927240 Journal of clinical pharmacology, 2009 Jan. : 88-102 -
Tasian SK, Park JR, Martin ET, Englund JAInfluenza-associated morbidity in children with cancer.
18240170 Pediatric blood & cancer, 2008 May : 983-7 -
Park JR, Eggert A, Caron HNeuroblastoma: biology, prognosis, and treatment.
18242317 Pediatric clinics of North America, 2008 Feb. : 97-120, x -
Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR, Jensen MCAdoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
17299405 Molecular therapy : the journal of the American Society of Gene Therapy, 2007 April : 825-33 -
Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JCLow-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
16170157 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005 Sept. 20 : 6481-8 -
Thomson B, Park JR, Felgenhauer J, Meshinchi S, Holcenberg J, Geyer JR, Avramis V, Douglas JG, Loken MR, Hawkins DSToxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
15382275 Pediatric blood & cancer, 2004 Oct. : 571-9 -
Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VIAsparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
15328169 Clinical cancer research : an official journal of the American Association for Cancer Research, 2004 Aug. 15 : 5335-41 -
Bradfield SM, Douglas JG, Hawkins DS, Sanders JE, Park JRFractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.
15022296 Cancer, 2004 March 15 : 1268-75 -
Wright JA, Bradfield SM, Park JR, Hawkins DSProlonged survival after invasive aspergillosis: a single-institution review of 11 cases.
12679641 Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology, 2003 April : 286-91 -
Park JR, Coughlin J, Hawkins D, Friedman DL, Burns JL, Pendergrass TCiprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
12461792 Medical and pediatric oncology, 2003 Feb. : 93-8
-
-
Presentations Title Event Location Date Infectious Complications of Pediatric Cancer Advanced Oncology Nursing unknown Oct. 1, 2009 Infectious Complications of Pediatric Cancer Advanced Oncology Nursing unknown June 1, 2009 Accessing Novel Therapies and Navigating the Maze - The Pediatric Oncologist's Perspective American Society of Clinical Oncology, Educational Session Orlando, FL June 1, 2009 Targeting Treatment to Improve Outcomes for Childhood Cancer Circle of Care Symposium, Seattle Children’s Hospital Seattle, WA May 1, 2009 Infectious Complications of Pediatric Cancer Advanced Oncology Nursing unknown Feb. 1, 2009 Infectious Complications of Pediatric Cancer Advanced Oncology Nursing unknown Feb. 1, 2009
Overview
- Board Certification(s)
-
Pediatric Hematology-Oncology
- Medical/Professional School
-
University of Vermont College of Medicine, Burlington
- Clinical Interests
-
Neuroblastoma, Novel therapies for recurrent and refractory cancer, Novel cellular immunotherapy
- Research Description
-
My research focus is to develop novel therapy for children with cancer with specific areas of focus on neuroblastoma and development of novel immunotherapy for children with relapsed and refractory cancers. The goal of my research is to translate laboratory findings into new therapies for children with cancer through close collaboration with both investigators at Seattle Children’s Research Institute, Fred Hutch, nationally and internationally. To facilitate this goal, I am chair of the Neuroblastoma Scientific Committee within Children's Oncology Group (COG) Consortium, leading development of clinical trials for children with neuroblastoma. In addition, I oversee the development of clinical trials for recurrent and refractory high risk neuroblastoma within the New Approaches to Neuroblastoma Therapy (NANT) consortium. I also oversee the development and implementation of cellular immunotherapy clinical trials for children with relapsed and refractory cancers at Seattle Children’s Research Institute and am funded through the NIH to lead the Pediatric Consortium for Cellular ImmunoTherapy in overcoming barriers to the implementation of novel cellular therapy. Nationally, I am co-investigator with Dr. Jensen for the Stand Up to Cancer Pediatric Dream Team and a member of the scientific steering committee for the Pediatric Clinical Immunotherapy Trials Network (PedCITN) as well as site investigator for the Pediatric Early Program Clinical Trials Network, both NCI funded consortia to develop novel therapies for children with recurrent and refractory cancer.
- Research Focus Area
-
Refractory and recurrent cancer, Sarcomas, Thyroid Cancer, Cancer biology, Cancer